A Nonsystematic Review on Risankizumab: a Novel Drug Recently Approved for Moderate to Severe Psoriasis

In April 2019, the USFDA has approved the humanized monoclonal antibody IgG, Risankizumab, that targets the protein p19 subunit of interleukin (IL-23), for the treatment of moderate to severe plaque psoriasis. The drug was developed by the AbbVie in collaboration with known Boehringer Ingelheim for the management similar immune-mediated inflammatory disorders like inflammatory bowel disease, rheumatic arthritis, etc. The recommended treatment in the case of plague psoriasis with Risankizumab was to begin with 2 initial doses amounts to 150 mg given at baseline (week 0) and again at week 4 that will be followed by 150 mg thereafter by 2 injections every 12 weeks. This article provides a hand on review regarding the drug with all the recent trials and indications.